Oberweis Asset Management Inc. Acquires 128,971 Shares of CareDx, Inc (NASDAQ:CDNA)

Oberweis Asset Management Inc. grew its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 43.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 423,471 shares of the company's stock after buying an additional 128,971 shares during the period. Oberweis Asset Management Inc. owned 0.79% of CareDx worth $9,067,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its position in CareDx by 12.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,116 shares of the company's stock worth $581,000 after purchasing an additional 3,016 shares during the period. Hsbc Holdings PLC lifted its stake in shares of CareDx by 6.9% during the 4th quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock valued at $365,000 after buying an additional 1,109 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in CareDx by 553.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock valued at $84,000 after buying an additional 3,322 shares in the last quarter. MetLife Investment Management LLC raised its holdings in CareDx by 7.4% during the 4th quarter. MetLife Investment Management LLC now owns 31,034 shares of the company's stock valued at $664,000 after acquiring an additional 2,134 shares during the period. Finally, Formula Growth Ltd. bought a new stake in CareDx during the 4th quarter valued at $1,670,000.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CDNA. Stephens reiterated an "overweight" rating and issued a $40.00 price target on shares of CareDx in a research report on Thursday, February 27th. Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and decreased their price target for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. HC Wainwright reduced their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. StockNews.com upgraded shares of CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. Finally, The Goldman Sachs Group reduced their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, CareDx has an average rating of "Moderate Buy" and a consensus target price of $30.33.

CareDx Trading Down 1.2 %

Shares of CareDx stock traded down $0.23 on Monday, hitting $18.25. 1,025,788 shares of the company traded hands, compared to its average volume of 853,324. CareDx, Inc has a 12-month low of $7.61 and a 12-month high of $34.84. The company has a market cap of $1.01 billion, a P/E ratio of -6.76 and a beta of 2.18. The firm's 50-day simple moving average is $19.07 and its 200 day simple moving average is $21.81.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million for the quarter, compared to the consensus estimate of $84.56 million. Analysts predict that CareDx, Inc will post -0.9 earnings per share for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.